Ebola cases sharpen focus on symptoms, transmission and UK preparedness
Ebola disease has returned to the center of public health attention after the World Health Organization declared a public health emergency of international concern on 17 May 2026 for outbreaks affecting the Democratic Republic of the Congo and Uganda. The current episode has prompted renewed scrutiny of a virus that remains uncommon in the UK, but can move quickly in settings where infection control fails and diagnosis is delayed.
The illness is caused by orthoebolaviruses, a group of viruses that infect humans and animals. Ebola was first identified in 1976 during near-simultaneous outbreaks in Zaire, now the DRC, and Sudan, now South Sudan. After a long period without reported human cases between 1979 and 1994, outbreaks have occurred with increasing frequency. The largest occurred in West Africa between 2014 and 2016, when urban transmission was seen on a scale not previously documented and more than 28,000 reported cases were recorded. Several countries, including the UK, imported cases linked to that epidemic.
A single sentence captures the central epidemiology: Ebola is rare in the UK, but it is never a disease to treat casually.
Transmission depends on close contact, not casual airborne spread
Ebola spreads through close contact with the body fluids of a person who is infected, sick, or has died from the disease. Contaminated objects, including needles and soiled clothing, can also transmit infection. In countries where Ebola circulates, people may acquire the virus from infected animals such as bats or non-human primates. Fruit bats are believed to be the natural reservoir, meaning the virus can persist in that host species and spill over into humans under the right circumstances.
The practical bedside implication is straightforward: the virus does not spread through intact skin, and there is no evidence that it transmits through coughing or sneezing in the way influenza or COVID-19 do. Infectiousness begins once symptoms appear, which means symptom recognition and rapid isolation are central to outbreak control. After recovery, however, the virus can persist in certain body compartments, including the testes, eyes and central nervous system. Sexual transmission from survivors has been documented, and viral detection in semen has been reported for more than a year after infection.
Early illness can mimic common infections before bleeding develops
Symptoms usually begin suddenly between 2 and 21 days after infection, with an average incubation period of 8 to 10 days. Early manifestations are non-specific: high temperature, extreme tiredness, muscle aches, sore throat and headache. In the first days of illness, these features can be confused with malaria, typhoid or meningitis, which is one reason Ebola can be missed before a patient becomes severely unwell.
Gastrointestinal symptoms often follow within days, including vomiting, diarrhoea and stomach pain. Some patients then develop rash, cough, shortness of breath, red eyes, bruising, and yellowing of the skin and eyes. In more severe cases, bleeding appears as the disease progresses, including blood in stool and bleeding from different parts of the body.
Laboratory confirmation is essential, and testing must be carried out under high-level biological containment because of the infection risk to staff and the environment. Early symptoms alone cannot confirm the diagnosis, yet early recognition is exactly what determines whether a patient enters a controlled pathway before widespread exposure occurs.
Severity remains high, with case fatality varying sharply by outbreak
Ebola is uncommon, but its lethality is what makes each outbreak a health emergency. The average case fatality rate is around 50%, although historical outbreaks have ranged from 25% to 90% depending on the virus species and on factors such as patient age and access to care. Those figures reflect both viral biology and health-system readiness. Where supportive treatment is delayed, outcomes worsen quickly.
For the UK population, the current risk remains low. Imported cases are extremely rare, and only four confirmed cases have been reported in the UK since 1976. No UK deaths have been recorded. NHS systems already have pathways and specialist centres in place for suspected cases, which reduces the chance that a single importation becomes a wider domestic event.
Supportive care, monoclonal antibodies and vaccines shape the response
There is no specific cure, but patients require intensive supportive treatment, including fluids and help maintaining blood pressure and oxygen levels. In Ebola, dehydration, shock and organ dysfunction can arrive quickly, so early fluid replacement and hemodynamic support are not adjuncts; they are core treatment.
Two monoclonal antibody treatments are available for Ebola caused by the Zaire virus species, the strain responsible for most major outbreaks. No licensed treatments are available for other species at present. The therapeutic gap matters because viral species determine both the available countermeasures and the expected public health response.
Prevention relies heavily on strict infection control. Patients must be isolated, and healthcare workers and carers need appropriate protective equipment because procedures such as inserting intravenous lines or handling blood carry particular risk. Bodies of people who die from Ebola remain highly infectious and require safe burial or cremation practices to prevent onward transmission.
Two vaccines are licensed to help prevent infection from the Zaire virus. One is a single-dose vaccine that can be deployed rapidly during an outbreak. The other requires two doses given 8 weeks apart, which makes it less suited to emergency containment but still useful for prevention. Neither vaccine currently protects against the Sudan virus species, although vaccines for that strain are under development.
UKHSA’s role extends from surveillance to outbreak support overseas
UKHSA monitors outbreaks overseas, assesses risk to the UK, and coordinates the public health response when needed. It also works with the Foreign, Commonwealth & Development Office, the Department for Transport and Border Force so that travellers returning from affected areas know what to do if they develop symptoms. Testing is available through the NHS for anyone who becomes unwell after travel to an affected region.
The UK Public Health Rapid Support Team was established after the 2014 to 2015 West Africa Ebola outbreak and is funded by the Department of Health and Social Care. It has delivered both in-person and remote deployments to support the World Health Organization in the DRC, the Republic of the Congo and South Sudan, with work spanning infection prevention and control, epidemiology, risk communication and community engagement, data modelling and readiness training at country and regional level.
Another arm of the response, the DHSC-funded International Health Regulations Strengthening Project delivered by UKHSA, has supported Ebola response capacity within partner countries and across the region. The work has included helping the Africa Centres for Disease Control and Prevention establish an expert advisory cell and strengthening cross-border surveillance and coordination in higher-risk settings, including an agreement between Uganda and South Sudan to improve health security collaboration.
For clinicians and public health teams, the current message is unambiguous: suspect Ebola early in the right travel context, isolate immediately, and move quickly to confirmatory testing under containment.